Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Northrop Grumman Corporation (NOC) Price & Performance

BioNTech SE - ADRTrade
Northrop Grumman CorporationTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Northrop Grumman Corporation — how do they compare? BioNTech SE - ADR trades at $93.03 (market cap $23.31B), while Northrop Grumman Corporation trades at $577.04 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 3.5× BioNTech SE - ADR's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXNOC
Market Cap
$23.31B$81.78B
Sector
HealthIndustrials
52-Week High
$119.34$768.02
52-Week Low
$83.89$496.02
Enterprise Value
$6.60B$95.77B
Dividend Yield
1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Northrop Grumman Corporation

Northrop Grumman (NOC) trades at $577.12, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $7.68, and raised full-year guidance, supported by a record $105 billion backlog. Revenue growth is steady, with 2026 projected at $42.9 billion, and profitability remains solid with a net income margin of 10.48%.

The outlook is positive, driven by strategic contracts like the $7.6 billion Sentinel program and defense spending tailwinds. Risks include margin pressures from specific programs and geopolitical uncertainties. Analysts are bullish with a consensus price target of $598.57, suggesting upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Northrop Grumman Corporation

Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.

Read more on NOC